Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era.
OBJECTIVE
Systemic chemotherapy is the only option for patients with unresectable/metastatic hepatocellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic areas. The aim of this study was to determine the efficacy of cisplatin-based combination chemotherapy and identify a subgroup of advanced HCC patients with favorable responses.


METHODS
The medical records of all consecutive patients with unresectable/metastatic HCC who received cisplatin-based combination chemotherapy between January 2003 and October 2009 were reviewed. Time to progression (TTP) and overall survival (OS) were determined using Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify prognostic factors for TTP and OS.


RESULTS
Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI], 1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program (CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as prognostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95% CI, 1.61 to 12.6; p=0.004) and PVT (HR, 2.12; 95% CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP.


CONCLUSIONS
Cisplatin-based combination chemotherapy in patients with advanced HCC has a low response rate and short TTP regardless of the chemotherapy regimen used. Patients with a good ECOG PS and without PVT can be considered candidates for cisplatin-based combination chemotherapy.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Nae Yu
NY
Kim
Jong Mu
JM
Sun
Yu-Jung
YJ
Kim
Keun-Wook
KW
Lee
Jee Hyun
JH
Kim
Soo-Mee
SM
Bang
Jin-Wook
JW
Kim
Sook-Hyang
SH
Jeong
Jong Seok
JS
Lee
J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8
16234567
Cancer. 2000 Dec 1;89(11):2266-73
11147597
Lancet Oncol. 2009 Jan;10(1):25-34
19095497
Gut. 2002 Jun;50(6):881-5
12010894
Cancer. 2002 Jan 15;94(2):421-7
11905412
Cancer. 2005 Feb 15;103(4):756-62
15637692
Eur J Cancer. 2004 Jul;40(10):1474-84
15196530
Korean J Hepatol. 2004 Jun;10(2):88-98
15218342
Cancer Chemother Pharmacol. 2004 Nov;54(5):385-90
15248028
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Hepatology. 2000 Apr;31(4):840-5
10733537
Cancer. 2000 Apr 1;88(7):1565-73
10738214
Cancer. 1988 Aug 1;62(3):479-83
2839280
Hepatology. 1998 Sep;28(3):751-5
9731568
Oncology. 1993;50(1):22-6
7678453
Cancer. 1985 Dec 15;56(12):2751-5
2413981
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Hepatology. 2001 Sep;34(3):529-34
11526539
Ann Oncol. 2009 Aug;20(8):1402-7
19502532
Trop Gastroenterol. 2005 Jul-Sep;26(3):115-8
16512457
World J Gastroenterol. 2000 Feb;6(1):134-135
11819542
J Clin Oncol. 2003 Jun 15;21(12):2294-8
12805329
Cancer. 2009 Mar 15;115(6):1245-52
19156918